Stryker Co. (NYSE:SYK) Shares Sold by S&CO Inc.

S&CO Inc. lessened its stake in Stryker Co. (NYSE:SYK) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,022 shares of the medical technology company’s stock after selling 595 shares during the quarter. S&CO Inc.’s holdings in Stryker were worth $5,788,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC increased its position in Stryker by 80.3% in the first quarter. Acadian Asset Management LLC now owns 56,006 shares of the medical technology company’s stock worth $20,036,000 after buying an additional 24,946 shares during the period. Catalytic Wealth RIA LLC acquired a new position in shares of Stryker during the first quarter valued at $287,000. Hillsdale Investment Management Inc. acquired a new position in shares of Stryker during the first quarter valued at $184,000. Davis R M Inc. grew its holdings in Stryker by 6.6% during the first quarter. Davis R M Inc. now owns 116,278 shares of the medical technology company’s stock worth $41,612,000 after acquiring an additional 7,241 shares during the period. Finally, Trustmark National Bank Trust Department acquired a new position in Stryker during the first quarter worth about $283,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This trade represents a 6.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 67,381 shares of company stock valued at $24,825,275 in the last three months. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. BTIG Research lifted their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. UBS Group increased their price target on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Robert W. Baird increased their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Royal Bank of Canada increased their price target on Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average target price of $393.65.

Stryker Trading Up 1.8 %

Shares of SYK stock opened at $390.08 on Friday. The stock’s fifty day moving average price is $364.07 and its two-hundred day moving average price is $347.40. The company has a market cap of $148.71 billion, a PE ratio of 41.81, a P/E/G ratio of 2.94 and a beta of 0.91. Stryker Co. has a fifty-two week low of $282.35 and a fifty-two week high of $392.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $2.46 EPS. Equities analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.